Abstract
We evaluated the antithrombotic efficacy of the low molecular weight heparin (LMWH) fraction PK 10169 in nine consecutive patients with acute pulmonary embolism documented by pulmonary angioscan and angiography. Therapy with PK 10169 was initiated by an i.v. bolus of 0.5 mg/kg, followed by a continuous intravenous infusion during the first 10 days; the drug was then given subcutaneously twice daily during the following 15 days. The dosage of PK 10169 was adjusted by daily measurements of anti-Xa and anti-IIa activities using amidolytic methods. For a dosage ranging from 1.4 to 4.1 mg/kg per day during the i.v. period and from 0.7 to 3.5 mg/kg per day during the s.c. period, the anti-Xa activity ranged from 4 to 8.7 PK U/ml and from 4.5 to 7.2 PK U/ml respectively. Clinical improvement was observed in all the patients and was consistent with progressive reperfusion evaluated by successive angioscans. No recurrence of pulmonary embolism occurred. No deleterious hemorrhagic side-effects were observed, even in two patients at high risk of bleeding. In this pilot study, the LMWH fraction PK 10169 proved to be an effective anticoagulant therapy during the first three weeks after pulmonary embolism in man.
Similar content being viewed by others
References
Aiach M, Michaud A, Balian JL, Lefebvre M, Woler M, Fourtillan J (1983) A new low molecular weight heparin derivative. In vitro and in vivo studies. Thromb Res 31:611
An International Multicenter trial (1975) Prevention of fatal post operative pulmonary embolism by low-doses of heparin. Lancet 2:45
Barrit DW, Jordan SC (1960) Anticoagulant drugs in treatment of pulmonary embolism. A controlled trial. Lancet 1:1309
Bomalski JS, Martin GJ, Hughes RL, Yao JST (1982) Inferior vena cava interruption in the management of pulmonary embolism. Chest 6:767
Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J (1984) A comparison of the antithrombotic and hermorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 35:613
Carter CJ, Kelton JG, Hirsh, J, Gent M (1981) Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. Thromb Res 21:169
Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M (1982) The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 59:1239
Contant G, Gouault-Heilmann M, Martinoli JL (1983) Heparin inactivation during blood storage: its prevention by blood collection in citric acid, theophylline, adenosine, dipyrimandole —CTAD mixture. Thromb Res 31:365
Contant G, Gouault-Heilmann M (1983) Automated amidolytic (anti-IIa) heparin assay. Thromb Haemostas 50:140 (Abstract)
Dalen JE, Banas Jr JS, Brooks HL, Evans GL, Paraskos JA, Dexter L (1969) Resolution rate of acute pulmonary embolism in man. N Engl J Med 280:1194
Dieval J, Moriniere P, Claisse JF, Roussel B, Toulemonde F, Delobel J, Fournier A (1984) Effectiveness and safety of low molecular weight heparin for hemodialysis and hemofiltration in uremic patients with high hemorrhagic risk. VIII International Congress on Thrombosis. Istambul 1984, p 288 (Abstract)
Glazier RL, Crowell EB (1976) Randomized prospective trial of continuous vs intermittent heparin therapy. J Am Med Assoc 236:1365
Gouault-Heilmann M, Huet Y, Contant G, Payen D, Bloch G, Rapin M (1983) Cardiopulmonary bypass with a low molecular weight heparin fraction. Lancet 2:1374 (Letter)
Gurewich V, Thomas DP, Stuart RK (1967) Some guidelines for heparin therapy of venous thromboembolic disease. J Am Med Assoc 199:166
Holm HA, Abildgaard U, Laerum F, Wolland T (1980) Heparin concentration (S 2222) and effect of heparin treatment (bleeding complications, pulmonary embolism and clearing of the thrombus), In: Lijnen HR, Collen D, Verstraete M (eds) Synthetic substrates in clinical blood coagulation assays. Martinius Nijhoff, The Hague, pp63–67
Huet Y, Gouault-Heilmann M, Fagon JY, Contant G, Brun-Buisson C (1984) Usefulness of low molecular weight heparin fractions in bleeding patients at high risk of thrombotic complications. Circulation 70 [Suppl 2]:365 (Abstract)
Jacques LB (1982) Heparin: an unique misunderstood drug. Trends Pharmacol Sci 3:289
Kakkar VV (1984) Prevention of post-operative venous thromboembolism by a new low molecular weight heparin fraction. Nouv Rev Fr Hematol 26:277
Lane DA, McGregor IR, Van Ross M, Cella G, Kakkar V (1979) Molecular weight dependence of the anticoagulant properties of heparin: intravenous and subcutaneous administration of fractionated heparins in man. Thromb Res 16:651
Mant MJ, O'Brien BD, Thong KL, Hammond GW, Birtwhistle RV, Grace MG (1977) Haemorrhagic complications of heparin therapy. Lancet 1:1133
National cooperative study (1973) the urokinase pulmonary embolism trial. Circulation 47 [Suppl 2]:1
Roussi JH, Houbouyan LL, Goguel AF (1984) Use of low molecular weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet 2:1183 (Letter)
Salzman EW, Deykin D, Shapiro MR, Rosenberg R (1975) Management of heparin therapy. Controlled prospective trial. N Engl J Med 292:1042
Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L (1980) Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 65:64
Thomas DP (1978) Heparin in the prophylaxis and treatment of venous thromboembolism. Semin Hematol 15:1
Tibutt DA, Fletcher EWL, Thomas ML, Sutton GC, Miller GAH (1975) Evaluation of a method for quantifying the angiographic severity of major pulmonary embolism by lowdoses of heparin. Lancet 2:45
Törnebohm E, Bratt G, Granqvist S, Lockner D (1984) Low molecular weigh heparin treatment of deep venous thrombosis (DTV). VIII International Congress on Thrombosis. Istambul July:322 (Abstract)
Tow DE, Wagner HN (1967) Recovery of pulmonary arterial blood flow in patients with pulmonary embolism. N Engl J Med 276:1053
Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ (1983) Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 30:219
Wilson III JE, Frenker EP, Pierce AK, Johnson Jr RL, Winga ER, Curry GC, Mierzwiak DS (1971) Spontaneous fibrinolysis in pulmonary embolism. J Clin Invest 50:474
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huet, Y., Gouault-Heilmann, M., Contant, G. et al. Treatment of acute pulmonary embolism by a low molecular weight heparin fraction. A preliminary study. Intensive Care Med 13, 126–130 (1987). https://doi.org/10.1007/BF00254798
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254798